Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
News Apr 16, 2012
Proteros biostructures GmbH announce that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.
Dr. Klaus Hinterding, Proteros CSO, stated: "We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai's research activities using our unique technology platform."
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE